Objective To explore cell subsets and molecules that changed specifically in patients with
multiple sclerosis (MS) who had an optimal response to natalizumab. Natalizumab is a
monoclonal antibody that inhibits the migration of activated immune cells to the central
nervous system. It shows high efficacy in modifying the natural history of MS and induces
freedom of disease activity in about 40% of treated patients with MS. Design Prospective
study of intrathecal immunoglobulin synthesis and cerebrospinal fluid lymphocyte subsets in …